We have identified desmoglein-2 (DSG-2) as the primary high-affinity receptor used by adenoviruses Ad3, Ad7, Ad11 and Ad14. These serotypes represent key human pathogens causing respiratory and urinary tract infections. In epithelial cells, adenovirus binding of DSG-2 triggers events reminiscent of epithelial-to-mesenchymal transition, leading to transient opening of intercellular junctions. This opening improves access to receptors, for example, CD46 and Her2/neu, that are trapped in intercellular junctions. In addition to complete virions, dodecahedral particles (PtDds), formed by excess amounts of viral capsid proteins, penton base and fiber during viral replication, can trigger DSG-2-mediated opening of intercellular junctions as shown by studies with recombinant Ad3 PtDds. Our findings shed light on adenovirus biology and pathogenesis and may have implications for cancer therapy.
Human adenoviruses have been classified into six species (A to F) with 55 known serotypes. Most adenovirus serotypes use the coxsackie adenovirus receptor (CAR) as a primary attachment receptor 1 . This is, however, not the case for species B adenovirus serotypes. Recently, we have suggested a new grouping of species B adenoviruses on the basis of their receptor usage 2 . Group 1 viruses (Ad16, Ad21, Ad35 and Ad50) nearly exclusively use CD46 as a receptor; group 2 viruses (Ad3, Ad7 and Ad14) share a common, unidentified receptor that is not CD46 and that we tentatively named receptor X. Group 3 (Ad11) preferentially interacts with CD46, but also uses receptor X if CD46 is blocked.
Species B adenoviruses are common human pathogens. Since 2005, a simultaneous reemergence of diverse species B serotypes, including serotypes Ad3, Ad7 and Ad14, has been observed. In 2007, a new, highly pathogenic and possibly more virulent strain of Ad14, Ad14a, was discovered at several sites in the US and Asia 3, 4 . We recently showed that Ad14a belongs to species B group 2 adenoviruses with regard to receptor usage 5 . Collectively, we will refer to all receptor X-using serotypes (Ad3, Ad7, Ad14, Ad14a and Ad11) as AdB-2/3. AdB-2/3 viruses have potential as gene transfer vectors, particularly for the treatment of tumors of epithelial origin 6 . Epithelial cells maintain several intercellular junctions (tight junctions, adherens junctions, gap junctions and desmosomes), a feature that is often conserved in epithelial cancers in situ and in cancer cell lines 7 . Both CAR and CD46 are trapped in intercellular junctions of epithelial cancer cells and are not accessible to adenoviruses that use these attachment receptors 8, 9 . In contrast, AdB-2/3 serotypes efficiently infect epithelial cancer cells, which is accomplished in part through induction of processes that are reminiscent of epithelial-to-mesenchymal transition (EMT) 8 , a cellular transdifferentiation program where epithelial cells lose characteristics such as intercellular junctions and gain properties of mesenchymal cells 10 . Another distinctive feature of AdB-2/3 viruses is their ability to produce subviral PtDds during their replication, consisting of adenovirus capsid proteins fiber and penton base 11 . PtDds cannot assemble from full-length penton base protein and require spontaneous N-terminal truncation by proteolysis between amino acid residues 37 and 38 (ref. 12) . This cleaved site is conserved in Ad3, Ad7, Ad11 and Ad14 but is not present in species C Ad2 and Ad5 (Supplementary Fig. 1a ). In the case of Ad3, PtDds are formed at a massive excess during viral synthesis (5.5 × 10 6 PtDds per infectious virus), and it has been hypothesized that PtDds contribute to virus escape and spreading 13 .
The first attempts to identify receptor X date back to 1995. These initial studies showed an interaction between Ad3 and a ~130-kDa HeLa cell protein 14 . Recently, several candidates for receptor X such as CD46, CD80 and/or CD86 were suggested [15] [16] [17] [18] . However, we and others have thus far been unable to verify that these proteins can serve as the high-affinity receptor for AdB-2/3 adenoviruses 2, [19] [20] [21] [22] [23] .
Here, using Ad3 virions and recombinant Ad3 PtDds as a probe for receptor X, we identify DSG-2 as a high-affinity receptor for AdB-2/3 serotypes. DSG-2 is a calcium-binding transmembrane glycoprotein belonging to the cadherin protein family. In epithelial cells, DSG-2 is a component of the cell-cell adhesion structure 24 . Its cytoplasmic tail interacts with a series of proteins that are in direct contact with regulators of cell adhesion and intercellular junctions 25 . It has been shown that DSG-2 is overexpressed in a series of epithelial malignancies, including gastric cancer 26 , squamous cell carcinomas 27 , melanoma 28 , metastatic prostate cancer 29 and bladder cancer 30 .
RESULTS
DSG-2 is a receptor for AdB-2/3 viruses Our previous studies showed that Ad3 binds at nanomolar affinity to a high-density cellular receptor 2 . Ad3 binding was sensitive to trypsin and could be blocked by EDTA, implying that binding required divalent cations. First we sought to identify the Ad3 capsid protein that mediates high-affinity binding to cells, which we would later use to search for the high-affinity receptor X. Notably, high-affinity binding of Ad5 to CAR and Ad35 binding to CD46 is mediated by the corresponding fiber knob 31 . Our previous studies, however, revealed that a recombinant, trimeric Ad3 knob could not completely block Ad3 virus binding, even when very high concentrations were used, indicating that other or additional capsid moieties are involved in Ad3 binding 32 . Consequently, we used recombinant Ad3 dodecahedra composed of Ad3 penton bases only (BsDds) or Ad3 PtDds (containing penton bases and fibers) ( Supplementary Fig. 1b ) 33 to compete for Ad3 binding. We showed that PtDds but not BsDds blocked attachment of Ad3 to cells (Fig. 1a) . PtDds also blocked binding of other AdB-2/3 adenoviruses, for example, Ad14, Ad14a and Ad11, if CD46 was also blocked ( Fig. 1a and Supplementary  Fig. 1c ). PtDds did, however, not inhibit binding of Ad5 and only Figure 1 Identification of receptor X using Ad3 virions and Ad3 PtDds. (a) Competition of 3 H-labeled Ad3 and Ad5 virus attachment to HeLa cells after preincubation with Ad3 BsDds, PtDds or adenovirus fiber knobs. Attachment in PBS-treated cells was taken as 100%. n = 5. Data are represented as means ± s.e.m. Ad3-PtDds versus Ad3 knob: P = 0.0033. (b) Competition of Ad3-GFP and Ad35-GFP virus infection. HeLa cells were pretreated with Ad3 fiber knob or PtDds at increasing concentrations and then exposed to Ad3-GFP (left) or Ad35-GFP (right) virus at an MOI of 100 PFU per cell. GFP expression was measured 18 h later by flow cytometry. Data are represented as means. s.d. was less than 10% for all data points. (c) Attachment of 3 H-labeled Ad3 and Ad35 viruses to human and nonhuman cell lines. Y79 and Ramos are human retinoblastoma and lymphoma cells, respectively. CHO cells are Chinese hamster ovary cells. MMC and TC1 cells are mouse mammary carcinoma and lung carcinoma cells, respectively. TC1-CD46 cells express human CD46. Shown are the average number of viral particles (VP) attached per cell. n = 5. (d,e) Identification of receptor X by affinity capture and MS-MS. Membrane protein fractions were prepared from HeLa and Ramos cells. Protein blots were hybridized with Ad5/35++ virions (d) and Ad3 virions or Ad3 PtDd (e). Binding was visualized with polyclonal antibodies against Ad35++ knob (d) or Ad3 knob (e) (see also Supplementary Fig. 1f ,g). Solubilized HeLa cell membrane lysates were also immunoprecipitated with DSG-2-specific mAb 6D8 crosslinked with protein A/G plus agarose. Western blotting of immunoprecipitates was performed with DSG-2-specific monoclonal antibody AH12.2 (anti-DSG-2-IP). (f) MS-MS analysis of the 160-kDa band. Top, structure of DSG-2. EC, extracellular domain; EA, juxtamembrane extracellular anchor domain; TM, transmembrane domain. Bottom, amino acid sequence of DSG-2. Highlighted are the peptide sequences captured by MS-MS analysis of the 160-kDa band. The triangles in the DSG-2 schematic (top) indicate the localization of the identified peptides with regard to the different domains. (g-i) Biacore plasmon surface resonance studies with recombinant human DSG-2 immobilized on sensor chips. Ad2, Ad3 and Ad5 at 5 × 10 9 viral particles per ml (g), various concentrations of PtDds (1, 3, 10, 30 or 100 µg ml -1 ) or 100 µg ml -1 BsDs (h) or PtDds and Ad3 fiber knob (i) were injected over the activated surface, and response signals were collected over the indicated time periods. partially blocked Ad35 binding ( Fig. 1a and Supplementary Fig. 1c ). Preincubation of cells with PtDds resulted in a better Ad3 binding inhibition than did Ad3 knob mixed with BsDds ( Supplementary  Fig. 1d ). The ability of PtDds to compete with Ad3 was also confirmed in transduction studies, where PtDds efficiently blocked an Ad3 vector (Ad3-GFP) but not an Ad35 vector (Ad35-GFP (that uses CD46 as a receptor)) ( Fig. 1b) . Ad3-GFP ( Supplementary Fig. 1e ) and Ad35-GFP 34 are wild-type Ad3-and Ad35-based vectors containing a CMV-GFP expression cassette inserted into the E3 region.
To select an optimal cell line for receptor X identification, we compared Ad3 virus binding to several human and animal cell lines ( Fig. 1c) . Ad3 did not bind rodent cells, suggesting that receptor X was not expressed or accessible to Ad3 in these cells. Of the ten human cell lines initially tested (HeLa, K562, SKOV3, 293, HT29, SKHep1, Saos, Y79 and Ramos), Ad3 binding was absent only on Ramos (human Burkitt's lymphoma) cells.
To identify adenovirus receptor candidates, we solubilized HeLa cell membrane proteins, separated them on polyacrylamide gels and blotted the gels. We hybridized the blots with viral particles and visualized binding with virus fiber knob-specific antibodies. Specific gel bands were excised and analyzed by tandem mass spectrometry (MS-MS). First, we tested whether this assay can detect a known adenovirus receptor, CD46. When we incubated filters with virions containing fibers with high affinity to CD46 (Ad5/35++) 35 , a single band was found that matched CD46 ( Fig. 1d) . Incubation of filters with Ad3 virions revealed two bands with molecular weights of 160 kDa and 90 kDa (Fig. 1e) . In addition to proteins in these two bands, Ad3 PtDds also reacted with HeLa proteins in the range of 130 kDa. Both 160-and 90-kDa bands were absent in Ramos cells, that is, cells that do not bind Ad3. The ~130-kDa PtDd-binding band appeared in both HeLa and Ramos cells, suggesting that it is not an Ad3 virus receptor. MS-MS analysis of the 160-kDa band identified 14 peptides matching human DSG-2 with a high confidence factor (20.8% protein coverage and Sequest cross correlation coefficient scores ranging from 2.6 to 5.5 for individual peptides) ( Fig. 1f ). Immunoprecipitation and western blot analyses of HeLa membrane proteins showed that both the 160-and the 90-kDa bands were recognized by DSG-2-specific antibodies (Fig. 1e) . This is in agreement with previous western blot studies showing that the 160-kDa band represents full-size DSG-2 and the 90-kDa band is a DSG-2 variant that lacks the intracellular domain, the transmembrane domain and the juxtamembrane extracellular anchor domain 36, 37 .
BIAcore surface plasmon resonance studies with sensors containing immobilized recombinant human DSG-2 showed that Ad3, but not Ad2 or Ad5, virions interact with DSG-2 ( Fig. 1g) . Recombinant PtDd but not BsDd particles bound DSG-2 ( Fig. 1h) . The K D (equilibrium dissociation constant) of the PtDd-DSG-2 interaction was 2.5 nM. PtDd binding to immobilized DSG-2 was specific, as soluble DSG-2 competed with it ( Supplementary Fig. 2 ). Surface plasmon resonance analysis of binding kinetics also showed that Ad3 fiber knob dissociates faster from DSG-2 than PtDds, which suggests the existence of additional DSG-2 binding sites within the fiber shaft or the requirement of fiber multimerization for high-affinity binding to DSG-2 ( Fig. 1i ; also see Supplementary Fig. 1d ). Loss-and gain-of-function studies were performed on cell lines to validate DSG-2 as a crucial receptor for AdB-2/3 binding and infection. Recombinant DSG-2 protein blocked the binding of Ad3 as well as of other AdB-2/3 adenoviruses, such as Ad7, Ad14, Ad14a and Ad11, to HeLa cells, but not the binding of Ad5 and Ad35 ( Fig. 2a) . Ad3-GFP infection was efficiently inhibited by DSG-2 protein but not by other structurally related members of the cadherin superfamily (DSG-1 and desmocollin-2) 38 (Fig. 2b) . These studies also showed that DSG-2 protein had no substantial effect on transduction by the CD46targeting vector (Ad35-GFP). We observed significant inhibition of Ad3 attachment with monoclonal antibodies (mAbs) against extracellular domains 3 and 4 ( Fig. 2c) (for a schematic of the DSG-2 structure, see Fig. 1f ). Transfection of HeLa cells with a pool of DSG2-specific siRNAs resulted in ~86% downregulation of surface DSG-2 abundance ( Supplementary Fig. 3a ). Ad3 attachment was ~70% lower in DSG2-specific siRNA-treated HeLa cells compared to control siRNAtreated cells (P < 0.001) ( Fig. 2d) . GFP expression after infection with Ad3-GFP was 91% lower in cells transfected with DSG2-targeting siRNA than in control siRNA-transfected cells ( Fig. 2e) . DSG2specific siRNA did not affect transduction with the CAR-targeting vector Ad5-GFP. However, DSG2-specific siRNA transfection also decreased binding and transduction with the CD46-specific vectors Ad35-GFP and Ad5/35-GFP (an AdS vector containing Ad35 fibers) ( Fig. 2e) . DSG2-targeting siRNA did not decrease CD46 abundance in HeLa cells (data not shown). At this point we cannot explain this phenomenon, but it seems to be specific to HeLa cells. No decrease in Ad35-GFP or Ad5/35-GFP transduction was detected in 293 cells ( Supplementary Fig. 3b-d) or breast cancer BT474 cells that were transfected with DSG2-targeting siRNA (data not shown).
siRNA-mediated DSG-2 downregulation also decreased viral cytolysis and spread in cells that were infected at 100% confluence at a multiplicity of infection (MOI) of one Ad3-GFP plaque-forming unit (PFU) per cell. Using adjusted MOIs (to achieve comparable percentages of GFP expression at 16 h after infection), we followed viral cytolysis over time and found larger lytic plaques in control siRNA-transfected cells than in DSG2-targeting siRNA-transfected cells at day 7 after infection. This was reflected in crystal violet staining of viable cells that remained attached to tissue culture wells, that is, cells that did not develop cytopathic effects from virus infection (Fig. 2f) . Quantitative analysis of cell viability showed significantly less killing of cells in which DSG-2 was downregulated by siRNA compared to control siRNA-treated cells (Fig. 2g) .
For gain-of-function studies, we selected a series of cell lines with various DSG-2 expression levels and measured Ad3-GFP transduction ( Fig. 3a and Supplementary Fig. 3e-g) . All cell lines that lacked DSG-2 expression (lymphoma Ramos, Raji, Mino and HH cells) were refractory to Ad3-GFP transduction but could be transduced by the CD46-targeting Ad5/35-GFP vector (because CD46 is expressed on these cells 39 ). DSG-2-positive K562 cells, in contrast, could be efficiently transduced with Ad3-GFP. Only about 70% of BJAB cells were DSG-2 positive and, consequently, transduction efficiency did not reach 100%. To conclusively prove the crucial role of DSG-2 in Ad3 infection, we ectopically expressed DSG-2 via lentivirus vector gene transfer in the histiocytic lymphoma cell line U937, which is refractory to Ad3-GFP transduction (Fig. 3b) . Ectopic DSG-2 expression in U937-DSG-2 cells conferred efficient Ad3 attachment and transduction, whereas Ad35 attachment and Ad5/35-GFP transduction was unaffected in these cells (Fig. 3c,d) . U937 cells were used in this study because lentivirus vector transduction of Ramos cells was inefficient. Notably, Ad5/35 and Ad35 attachment to U937-DSG-2 cells is mediated through CD46 and can be blocked by soluble CD46 (data not shown). 200  160  Counts  Counts  Counts  120  80  40  0   200  160  120  80  40  0   200  160  120  80  40  0   200  160  120  80  40  0   200  160  120  80  40  0   10  0 10  1 
DSG-2 localization in human cells
As expected, we found DSG-2 in cell membranes of normal epithelial tissues (foreskin and colon) and epithelial cancers (breast and ovarian cancer) ( Fig. 4a) . Confocal immunofluorescence microscopy studies of polarized colon cancer T84 and CaCo-2 cells showed colocalization of DSG-2 and the intercellular junction protein claudin-7 ( Fig. 4b and Supplementary Fig. 4a,b) . In stacked XZ image sections ( Fig. 4b ) (or XY sections taken at different depth of the cell layer ( Supplementary  Fig. 4a) ), DSG-2 appeared at the distal end of intercellular junctions. DSG-2 also colocalized with the adherens junction protein E-cadherin in epithelial cells (Supplementary Fig. 4c,d) . Fifteen minutes after adding Cy3-labeled Ad3 to polarized cells, we could detect viral particles in association with junction-localized DSG-2 ( Fig. 4c and Supplementary  Fig. 4b ). We obtained similar results with normal small airway epithelial cells incubated with PtDds for 15 min, as shown by triple labeling of Cy5-PtDd, DSG-2 and E-cadherin ( Fig. 4d) . PtDd signals were on cell membranes ( Fig. 4d) and in the cytoplasm, most likely reflecting internalized particles (see also Supplementary Fig. 4e) .
In contrast to polarized epithelial cell lines, in nonpolarized cells, such as HeLa cells, intercellular junctions (that is, membrane-localized claudin-7 and E-cadherin signals) were absent (Fig. 4e) . DSG-2 and Cy3-Ad3 particles were dispersed over the cell surface (Fig. 4e) .
Our studies on Ad3 infection of HeLa cells ( Figs. 1 and 2) indicate that DSG-2 also acts as a receptor in nonpolarized cells. In this context, it is noteworthy that we detected DSG-2 and Ad3 binding and transduction in human platelets and granulocytes ( Supplementary  Fig. 5a,b) . Although these findings are relevant for Ad3 pathogenesis and the intravascular application of Ad3 vectors for gene therapy purposes, we focused in this study on analyzing the consequences of Ad3-DSG-2 interaction in polarized epithelial cells.
Ad3 interaction with DSG-2 triggers EMT
Recently, we found that AdB-2/3 interaction with epithelial ovarian cancer cells triggers EMT 8 . EMT is characterized by increased expression of mesenchymal markers, increased expression of extracellular matrix compounds, decreased expression of epithelial markers, altered intracellular localization of transcription factors and activation of kinases 7 . Here we attempted to prove that Ad3 interaction with DSG-2 triggers EMT-like events. To avoid potential side effects of viral gene expression on cell morphology, we used ultraviolet light (UV)-inactivated adenovirus particles and recombinant Ad3 PtDds. Overall, the results with both types of particles were similar. Incubation of epithelial cancer cells with PtDds ( Fig. 5) or UV-inactivated Ad3 (data not shown) caused remodeling of junctions as reflected by the decrease in junctionlocalized claudin-7 ( Fig. 5a ) and E-cadherin signals (Fig. 5b) . Furthermore, after PtDd treatment, we found stronger immunofluorescence signals of the mesenchymal markers vimentin and lipocalin-2 ( Fig. 5c,d) . To identify intracellular signaling pathways triggered by PtDd interaction with DSG-2, we studied mRNA expression profiles. Twelve hours after incubation of polarized BT474 cells with PBS, BsDds or PtDds, we analyzed mRNA with Affymetrix human ST gene arrays. We found that PtDd treatment resulted in >150% upregulation of 430 genes and >45% downregulation of 352 genes when compared to PBS-treated cells (Fig. 5e ). The list of altered genes was further processed with Pathway-Express software 40 . This computation suggested that PtDds mediated marked activation of a number of signaling pathways involved in EMT, including phosphatidylinositol, extracellular signal-regulated kinase 1 and 2 (ERK1/2) (also known as mitogen-activated protein kinase (MAPK)), Wnt, adherens junctions, focal adhesion and regulation of actin cytoskeleton signaling pathways (Supplementary Fig. 6) .
Western blot analysis with phosphorylation-specific antibodies showed that PtDds, but not BsDds, triggered the activation of phosphatidylinositol 3-kinase (PI3K) and ERK1/2 , key kinases involved in EMT (Fig. 5f) . Activation of these pathways was also triggered by DSG-2-specific mAbs (6D8, and to a lesser degree 10D2 and 13B11) but not by mAbs directed against GAPDH. PtDd activation of pathways was mediated by DSG-2, because ERK1/2 and PI3K phosphorylation was decreased in PtDd-treated cells transfected with DSG2-targeting siRNA compared to control siRNA-transfected cells (Fig. 5f) . Finally, PtDd-triggered phosphorylation of kinases was absent when cells were pretreated with the ERK1/2 inhibitor UO126 or the PI3K inhibitor wortmannin (Fig. 5f) . Taken together, our data suggest that Ad3 or Ad3 PtDd binding to DSG-2 activates pathways that are involved in EMT.
Ad3 and PtDd increase access to CD46, Her2/neu and EGFR
To test whether Ad3 virion-or Ad3 PtDd-triggered EMT also results in opening of intercellular junctions, we studied barrier properties in monolayers of epithelial cells. First we measured the flux of 4-kDa FITCdextran through confluent polarized BT474 cells cultured in transwell chambers. We found that PtDd but not BsDd incubation significantly increased the permeability coefficient compared to PBS (Fig. 6a) . We then tested whether Ad3-or PtDd-triggered EMT and transient junction opening would increase access to proteins that are normally not accessible owing to epithelial cell junctions. An example for such a junction-localized receptor is CD46, the high-affinity receptor for Ad35
and Ad5/ 35 (ref. 8) . We confirmed that a large number of CD46 molecules localizes to junctions of BT474 cells (Fig. 6b) . PtDd pretreatment significantly increased the attachment of 3 H-Ad35 to BT474 cells when compared to BsDd treatment (P < 0.05) (Fig. 6b) . We also observed an enhancing effect of PtDds on transduction of CD46-targeting adenovirus vectors in vivo in subcutaneous epithelial tumors (Fig. 6c) . Intravenous injection of PtDds 8 h before intravenous application of the CD46-targeted β-galactosidase expressing vector Ad5/35-βGal increased viral transduction. β-galactosidase activity, measured in tumor lysates 3 d after adenovirus injection, was 2.3 ± 0.2 × 10 5 relative light units (RLU) per µg protein, 2.7 ± 0.6 × 10 5 RLU per µg protein and 38 ± 3.5 × 10 5 RLU per µg protein for mice that were mock-injected, BsDdinjected and PtDd-injected, respectively. In another line of experiments in breast cancer cell cultures, we found that Her2/ neu, the receptor for the widely used monoclonal antibody Herceptin co-stained with the intercellular junction protein claudin-7 (Fig. 6d) . This suggests that not all Her2/ neu molecules are accessible to Herceptin. Incubation of the Her2/neu-positive breast cancer cell line BT474 with PtDds triggered relocalization of Her2/neu to the cell surface (Fig. 6e) . We therefore tested whether Ad3 or Ad3 PtDds would improve BT474 cell killing by Herceptin. In agreement with earlier studies 41 , Herceptin caused death of approximately 25% of BT474 cells (Fig. 6f) .
Preincubation of BT474 cells with UVinactivated Ad3 particles or PtDds increased
Herceptin cytotoxicity by more than twofold (Fig. 6f) . Incubation with UV-inactivated Ad5 particles or BsDds had no effect on Herceptin killing (Fig. 6f) . In addition, Herceptin and Herceptin together with PtDds had no cytotoxic effect on the Her2/ neu-negative breast cancer cell line MDA-MB-231 ( Supplementary  Fig. 7a) . The enhancing effect of PtDds and Ad3 on Herceptin killing of BT474 cells was mediated by DSG-2, as downregulation of DSG-2 in BT474 cells by DSG2-targeting siRNA abolished this effect (Fig. 6g) . We also studied whether inhibition of key pathways involved in EMT affects the enhancing effect of PtDds on Herceptin cytotoxicity. These studies showed that inhibition of PI3K by wortmannin, as well as inhibition of ERK1/2 by UO126 counteracted PtDd enhancement of Herceptin therapy (Fig. 6g) . Notably, intravenous injection of PtDds (2 mg per kg body weight) into BT474-M1 tumor-bearing mice 12 h before Herceptin treatment resulted in elimination of tumors, an outcome that could not be achieved with Herceptin injection alone (Fig. 6h) . Furthermore, PtDd pretreatment increased killing of epidermal growth factor receptor (EGFR)-positive colon cancer LoVo cells by the EGFR-specific mAb Erbitux in vitro (Supplementary Fig. 7b ).
DISCUSSION
In this study we find that DSG-2 is a crucial receptor for infection of epithelial cells by a series of human adenoviruses that are common pathogens. Adenovirus interaction with DSG-2 results in the opening of intercellular junctions, thus increasing access to receptors trapped there. The use of complete Ad3 particles or PtDds as a receptor probe was instrumental in the identification of DSG-2 as the attachment receptor for Ad3, Ad7, Ad11 and Ad14. Previous attempts with Ad3 fiber knob domains as bait did not yield meaningful receptor candidates 32 . Our competition and surface plasmon resonance studies indicate that the DSG-2-interacting domains within Ad3 are formed by the fiber only in the spatial constellation that is present in viral particles. This clearly widens our understanding of adenovirus attachment mechanisms, which have been thought to involve only a high-affinity interaction between the fiber knob and the cellular receptor, that is, CAR or CD46.
During replication of Ad5, excess production of fiber results in the disruption of epithelial junctions either by interfering with CAR dimerization (which is crucial for maintenance of junctions) or by triggering intracellular signaling that leads to reorganization of intercellular junctions 42, 43 . Both mechanisms could also be involved in opening of intercellular junctions mediated by the interaction of Ad3 or Ad3 PtDds with DSG2. We have experimental support for intracellular signaling triggered by Ad3 and PtDd binding to DSG-2 in epithelial cells. Immunofluorescence, PI3K and ERK1/2 phosphorylation, mRNA expression array and metabolic pathway inhibition data suggest that Ad3 and PtDds trigger EMT in epithelial cells, resulting in transient opening of intercellular junctions. Intercellular junction opening mediated by interaction of Ad3 particles or recombinant PtDds with DSG-2 is further supported by increased cell permeability and access to receptors that are trapped in intercellular junctions (CD46 and Her2/neu). Along this line, a recent study showed that antibodies against the extracellular domain of DSG-2 resulted in the opening of intercellular junctions in CaCo-2 cell monolayers 44 .
Ad3 virion-and PtDd-triggered EMT, that is, the dissociation of the intercellular junctions, seems to have a key biological role. We speculate that specifically the massive overproduction of PtDds during viral infection and their interaction with DSG-2 facilitate the Figure 2d and 48 h later treated with Ad3 or PtDds and Herceptin as described in g. For inhibitor studies, BT474 cells were incubated with the indicated agents overnight. Cells were washed and treated with PtDd or UV-inactivated Ad3 and Herceptin as described above. n = 5, PBS versus wortmannin, UO126: P < 0.05. (h) PtDd-mediated enhancement of Herceptin therapy in vivo. Shown is the tumor volume of individual mice at different days after BT474-M1 cell injection. The day of saline or Herceptin injection is indicated by an arrow. PtDds were injected 12 hours before Herceptin.
Figure 6
Opening of intercellular junctions in epithelial breast cancer cells by interaction of Ad3 virions or PtDds with DSG-2. (a) FITCdextran diffusion through monolayers of BT474 cells. BT474 cells cultured in a transwell chamber with 0.4 µm pore size were treated with 0.5 µg ml −1 BsDds or PtDds or 2 × 10 8 adenovirus particles per ml for 2 h, and then lateral viral spread in epithelial cells and, potentially, the penetration of adenovirus into subepithelial cell layers and the blood stream. Our findings that DSG-2 is an attachment receptor that facilitates further viral spread, sheds light on the Ad3 infection mechanism of the respiratory tract epithelium. Furthermore, the observation that Ad3 binds DSG-2 on platelets and granulocytes has potential implications on systemic spread of this virus once it has entered the blood stream. Although mouse DSG-2 shares 76% protein sequence homology with human DSG-2 (ref. 45) , our data, showing that mouse cells are refractory to Ad3-GFP infection, indicate that mouse DSG-2 cannot function as an Ad3 receptor. To study the pathogenesis of AdB-2/3 serotypes, transgenic mice that express human DSG-2 under the control of adequate endogenous regulatory elements, resulting in DSG-2 expression in a pattern and in amounts similar to humans, would be a key tool.
DSG-2 has been proposed as a marker for epithelial tumors 46 . The epithelial phenotype of cancer cells and the ability to form physical barriers represent a mechanism that restricts access of drugs, antibodies, oncolytic viruses and immune cells to the sites of tumors, thus diminishing the efficacy of such therapeutic modalities 47 . We have shown here, in three examples (Ad5/35 vectors, Herceptin and Erbitux), that this problem in cancer therapy can perhaps be addressed by the use of DSG-2-interacting Ad3 components. Although our initial data with PtDds are promising, studies in appropriate DSG2transgenic mouse models are required to gain further preclinical safety information for this approach.
In conclusion, we report the discovery of the high-affinity receptor for a number of common human adenoviruses. Our study contributes to the understanding of how adenoviruses induce cellular processes to gain access to epithelial tissue and may have implications for improving cancer therapies.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. Accession codes. Gene array data has been deposited at National Center for Biotechnology Information Gene Expression Omnibus with accession number GSE24138 . 
